IL210175A0 - Fn14/trail fusion proteins - Google Patents
Fn14/trail fusion proteinsInfo
- Publication number
- IL210175A0 IL210175A0 IL210175A IL21017510A IL210175A0 IL 210175 A0 IL210175 A0 IL 210175A0 IL 210175 A IL210175 A IL 210175A IL 21017510 A IL21017510 A IL 21017510A IL 210175 A0 IL210175 A0 IL 210175A0
- Authority
- IL
- Israel
- Prior art keywords
- fusion proteins
- trail fusion
- trail
- proteins
- fusion
- Prior art date
Links
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13353208P | 2008-06-30 | 2008-06-30 | |
| PCT/US2009/003886 WO2010005519A1 (en) | 2008-06-30 | 2009-06-30 | Fn14/trail fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL210175A0 true IL210175A0 (en) | 2011-03-31 |
Family
ID=41278748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL210175A IL210175A0 (en) | 2008-06-30 | 2010-12-22 | Fn14/trail fusion proteins |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8039437B2 (https=) |
| EP (2) | EP2297198B1 (https=) |
| JP (1) | JP5475766B2 (https=) |
| CN (1) | CN102137869B (https=) |
| AU (1) | AU2009269141B2 (https=) |
| CA (1) | CA2729351C (https=) |
| IL (1) | IL210175A0 (https=) |
| SG (1) | SG191698A1 (https=) |
| WO (1) | WO2010005519A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| CN102206281B (zh) * | 2011-03-28 | 2014-04-09 | 中国人民解放军第三军医大学第一附属医院 | 融合蛋白tetph、表达载体及其构建方法 |
| WO2012145568A1 (en) | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| PL397167A1 (pl) * | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
| US9238034B2 (en) | 2013-07-09 | 2016-01-19 | The Translational Genomics Research Institute | FN14 antagonists and therapeutic uses thereof |
| JP2017525370A (ja) | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 |
| AU2016227322A1 (en) * | 2015-03-03 | 2017-09-21 | Kahr Medical Ltd | Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases |
| JP6981973B2 (ja) | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11267856B2 (en) | 2017-02-27 | 2022-03-08 | Shattuck Labs, Inc. | CSF1R-CD40L chimeric proteins |
| US20190367579A1 (en) | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
| EP4249503A3 (en) | 2017-02-27 | 2023-12-20 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| CN111819198A (zh) * | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| US20220267409A1 (en) | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| EP2298333A3 (en) | 1999-12-20 | 2012-05-02 | Immunex Corporation | Tweak receptor |
| US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| US7378089B2 (en) | 2001-10-02 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Gene therapy for the prevention of autoimmune disease |
| MX352180B (es) * | 2002-04-09 | 2017-11-13 | Biogen Ma Inc | El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak. |
| DE60336746D1 (de) * | 2002-10-29 | 2011-05-26 | Anaphore Inc | Trimer-proteine zur trimer-zytokine |
| DE602004006871T2 (de) * | 2003-07-24 | 2008-02-07 | Amgen Inc., Thousand Oaks | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen |
| US7285522B2 (en) | 2004-08-25 | 2007-10-23 | The Clorox Company | Bleaching with improved whitening |
-
2009
- 2009-06-30 CA CA2729351A patent/CA2729351C/en active Active
- 2009-06-30 US US12/494,680 patent/US8039437B2/en active Active
- 2009-06-30 EP EP09788855.6A patent/EP2297198B1/en active Active
- 2009-06-30 JP JP2011516335A patent/JP5475766B2/ja active Active
- 2009-06-30 SG SG2013049333A patent/SG191698A1/en unknown
- 2009-06-30 EP EP12001349A patent/EP2460827A1/en not_active Ceased
- 2009-06-30 CN CN200980133865.2A patent/CN102137869B/zh active Active
- 2009-06-30 WO PCT/US2009/003886 patent/WO2010005519A1/en not_active Ceased
- 2009-06-30 AU AU2009269141A patent/AU2009269141B2/en active Active
-
2010
- 2010-12-22 IL IL210175A patent/IL210175A0/en active IP Right Grant
-
2011
- 2011-08-11 US US13/208,091 patent/US8329657B2/en active Active
-
2012
- 2012-08-15 US US13/586,479 patent/US20130065815A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010005519A1 (en) | 2010-01-14 |
| SG191698A1 (en) | 2013-07-31 |
| US20100048478A1 (en) | 2010-02-25 |
| JP5475766B2 (ja) | 2014-04-16 |
| EP2297198A1 (en) | 2011-03-23 |
| US8039437B2 (en) | 2011-10-18 |
| EP2460827A1 (en) | 2012-06-06 |
| CN102137869A (zh) | 2011-07-27 |
| CN102137869B (zh) | 2018-07-06 |
| CA2729351A1 (en) | 2010-01-14 |
| AU2009269141A1 (en) | 2010-01-14 |
| US20120028909A1 (en) | 2012-02-02 |
| CA2729351C (en) | 2017-01-24 |
| US20130065815A1 (en) | 2013-03-14 |
| EP2297198B1 (en) | 2014-12-17 |
| AU2009269141B2 (en) | 2013-04-04 |
| US8329657B2 (en) | 2012-12-11 |
| JP2011526891A (ja) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL210175A0 (en) | Fn14/trail fusion proteins | |
| IL275846A (en) | ACTRIIB–FC truncated fusion proteins | |
| IL215005A0 (en) | Ox40/trail fusion proteins | |
| IL202128A0 (en) | Immunoglobulin fusion proteins | |
| IL196889A0 (en) | Albumin-insulin fusion proteins | |
| EP2413969A4 (en) | FUSION PROTEINS WITH DOG FC ELEMENTS | |
| ZA200908649B (en) | Rage fusion proteins | |
| IL204839A0 (en) | Albumin fusion proteins | |
| BRPI0918947A2 (pt) | proteína de fusão de anticorpo | |
| IL205257A0 (en) | Anti-rsv g protein antibodies | |
| ZA201106638B (en) | Anti-angiogenic fusion proteins | |
| IL205716A0 (en) | Formulations for taci-immunoglobulin fusion proteins | |
| SG10202100341XA (en) | Npp1 fusion proteins | |
| IL236236A (en) | Antibodies to the fam26f polypeptide | |
| LT2144924T (lt) | Sulieto baltymo vakcina | |
| GB2465683B (en) | LL-37 Related Fusion Peptides | |
| EP2657337A4 (en) | FUSION PROTEIN | |
| ZA201207425B (en) | Fusion protein | |
| GB0725201D0 (en) | Peptide fusion proteins | |
| GB2465684B (en) | Biocidal fusion peptides | |
| GB0700759D0 (en) | Novel fusion protein | |
| GB0713169D0 (en) | Fusion proteins | |
| GB0709707D0 (en) | Novel fusion protein | |
| GB0919753D0 (en) | Interferon lambda fusion proteins | |
| GB0904647D0 (en) | Modified receptor fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |